RxDoctor Payments Data

Jessica Brown, NP

Nurse Practitioner · Tarboro, NCNPI 1376781609

Payments from drug & device makers

$2,853in general payments, 2019–2025

Across 160 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$677
  • Johnson & Johnson$474
  • Novartis$367
  • Sanofi-aventis U.S. LLC$190
  • Medtronic$162
  • AstraZeneca$138
  • plus $844 from 16 others

What the payments were for

  • Food & beverage$2,853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,853 in reported general payments places this provider in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

See all nurse practitioner providers in North Carolina

Medicare billing

Part B allowed, 2024
$43,666
Medicare patients
183
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban209$174,342
EliquisApixaban211$171,418
Repatha SureclickEvolocumab109$69,606
EntrestoSacubitril/Valsartan80$68,346
MultaqDronedarone Hcl50$42,638
JardianceEmpagliflozin14$11,565
Ranolazine ErRanolazine59$4,713
Valsartan182$3,744
Hydralazine Hcl233$3,446
Atorvastatin Calcium321$2,907
Metoprolol Succinate269$2,371
Diltiazem 24hr Er (Cd)Diltiazem Hcl118$2,242
Carvedilol311$1,798
Furosemide444$1,671
Amlodipine Besylate356$1,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$474$174,342209 claims
PfizerEliquis$55$171,418211 claims
NovartisEntresto$367$68,34680 claims
Sanofi-aventis U.S. LLCMultaq$190$42,63850 claims
Boehringer IngelheimJardiance$96$11,56514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,393 nurse practitioner providers in North Carolina.

Other nurse practitioner in Tarboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →